Garuda Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Garuda Therapeutics, Inc. - overview
Established
2021
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Established in 2021 and based in Massachusetts, US, Garuda Therapeutics, Inc. operates as a biopharmaceutical company that creates hematopoietic stem cell therapies. The company was cofounded by Dr. Dhvanit Shah, Dr.
David Scadden, and Dr. Sean Morrison. In March 2025, Garuda Therapeutics, Inc. raised USD 50 million in series A funding from new investor Kyowa Kirin.
Returning investors OrbiMed Advisors, Northpond Ventures, Cormorant Asset Management, and other unspecified investors also participated in the round. Garuda is developing a hematopoietic stem cell platform that has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells. The company's platform technology for generating self-renewing blood stem cells is poised to provide patients with broad access to HLA-compatible transgene-free blood stem cell therapies. The company will use the March 2025 funding to support the expansion of its products.
Current Investors
OrbiMed Advisors, Aisling Capital, Mass General Brigham Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.garudatx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.